| Modality | Indication | Targets | Stage | Company | Project No. | Detail | |
|---|---|---|---|---|---|---|---|
| 1 | Clinical Phase 2 trial of DD01, a Novel Long-acting GLP-1/GCG dual agonist in patients with MASH | ||||||
| rProtein | MASH (Metabolic Associated Steatohepatitis) | GLP-1/Glucagon receptor | Phase 2 | D&D Pharmatech Inc. | RS-2025-02073063 | ||
| 2 | Global Clinical Trial and Commercialization for Development of Next-generation Long-acting Glucagon (HM15136 ) for Congenital Hyperinsulinism (CHI) | ||||||
| rProtein | Congenital hyperinsulinism | glucagon | Phase 2 | Hanmi Pharm. Co., Ltd. | HN21C0601 | ||